Ionis Pharmaceuticals, Inc.
Clinical trials sponsored by Ionis Pharmaceuticals, Inc., explained in plain language.
A biopharmaceutical company developing RNA-targeted therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug shows promise in preventing hereditary swelling attacks Results expected Dec 2026 (estimated)
- New drug shows promise for dangerous fat levels in blood Results expected Mar 2027 (estimated) May already have reported ↗
- Experimental drug ION717 aims to slow fatal brain disease Results expected Apr 2027 (estimated)
- New hope for rare fat disorder: safety trial of olezarsen underway Results expected Jun 2027 (estimated) May already have reported ↗
- New drug aims to unlock speech in angelman syndrome Results expected Aug 2027 (estimated)
-
Early safety trial of ION269 for Alzheimer's in down syndrome ends after just one participant
Disease control Stopped earlyThis early-stage study tested a drug called ION269 in adults with Down syndrome who also showed signs of Alzheimer's disease. The goal was to check if the drug was safe and tolerable when injected into the spinal fluid. Only one person took part, and the study was stopped early, …
Phase 1 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Scientists hunt for clues in rare genetic brain disorder
Knowledge-focused Stopped earlyThis study aimed to observe how MECP2 duplication syndrome progresses over time by measuring biological markers in spinal fluid and blood, and by tracking changes in development, behavior, and seizures. It enrolled 29 males aged 1 month to 65 years with a confirmed genetic diagno…
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC